In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with J.D. Mowery, President and Chief Executive Officer at KBI Biopharma. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with J.D., covering: The experience of bringing a product to market... and then many years later seeing that product used on his wife to help bring his sons into the worldHow bringing a commercial facility online for Genentech to impact thousands of patients compares to the ‘vain to vain’, hospital-based, one-off patient CAR-T product for JunoWhy the ethos of taking care of the person on your left and the person on your right helps with the scale-up of a multi-national global CDMOThe emergence of a partnership-based, absorption business model between innovators and CDMOs in the wake of the shift in capital marketsWhat the next generation CDMO will look like… J.D. is an accomplished leader with a distinguished reputation in the biopharma industry and proven expertise in guiding global innovators and contract development and manufacturing organizations (CDMOs) for nearly 25 years. Throughout his diverse career, J.D. has demonstrated strategic vision and the ability to drive all aspects of an organization, including operations, R&D, manufacturing, tech transfer, facility construction, business development, employee growth, and investor relations. He is an expert in diverse modalities, including small molecules, biologics, and cell and gene therapy. J.D. has held executive leadership positions as  Head of Operations at Lonza and Executive Vice President of U.S. Operations at AGC Biologics. He has also held influential roles at innovators, including Genentech, Celgene, and Juno, and most recently served as Chief Operating Officer at Treadwell Therapeutics. J.D. holds a Bachelor of Science from George Fox University and an MBA from Marylhurst University. Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with TJ Higley, CEO at Microsize. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with TJ, covering: The fast, easy, scalable, precise, and non-patent-protected benefits of micronizationHow a synergistic capability alliance led to the eventual sale of his business to Lonza CapsugelThe risks and realities of being an entrepreneur acquiring an organization, and then the collective rewards by incentivizing a teamHow a ‘getting the band back together’ call led to TJ taking back the site he once sold to create MicrosizeThe importance of strategic partnerships and recognizing that you can’t do everything yourself TJ joined Microsize in 2022 as CEO to lead the company into the next growth phase. TJ brings 25 years of experience in the pharmaceutical market, most uniquely as a former owner and executive leader of Powdersize, Inc., the original and first CMO focused on pharmaceutical micronization in the US. TJ led both the business development efforts and oversaw the site quality team during his tenure, culminating in the acquisition of the company by Capsugel in 2015 and the integration into Lonza in 2017. Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Howard Berman, CEO and Chairman of the Board at Coya Therapeutics Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Howard, covering: How a neurology appointment with his father led to the creation of a biotech company focused on neurodegenerative, autoimmune, and metabolic diseasesHaving the DNA of an entrepreneur but taking the time to gain a big pharma foundationThe harsh realities and characteristics required to start, fund, and grow a clinical-stage biotechnology companyThe need as a biotech CEO to be bullish, have confidence in your partners and be passionate about your disease... while celebrating the little successesHoward co-founded Nicoya Health in 2020 to realize the vision and research of Dr. Stanley Appel. He merged the company with Coya Therapeutics in 2021, where he currently serves as Chairman and CEO He has over 18 years of entrepreneurial and industry experience working at the interplay of science and business. His experience offers him a unique combination of business acumen and scientific credibility with the ability to assess, quantify, and bridge both disciplines. Howard gained corporate experience with increasing responsibilities and positions as a Medical Science Liaison at AbbVie. He spent 7.5 years launching Venetoclax in CLL and later, supporting numerous solid tumor assets. He also served in leadership roles at Novartis Pharmaceuticals and later Eli Lilly where he was the scientific point of contact between the company and key opinion leaders for the development and initiation of collaborations, clinical trials and investigator-initiated trials. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Pamela Bush, Chief Business Officer at Predictive Oncology. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Pam, covering: The key aspects to successful deal-making learned over a decade with Eli LilyHow a passion for curing cancer led Pamela to an opportunity to impact thousands of promising candidates directlyHow active machine learning is being used to screen molecules, help companies fail fast, and increase the success of a molecule in clinical trialsThe challenge of selling a disruptive, game-changing platform that could become a vital decision tool in the future Pamela Bush, Ph.D. has over twenty years of experience in venture creation, finance, and business development in the life sciences industry. Pamela is the Chief Business Officer for Predictive Oncology where she leads the strategy and business development activities across the portfolio. Prior to joining Predictive Oncology, Pamela worked at Eli Lilly & Company in various roles including Corporate Business Development, Finance and Patient Services. In addition to her Lilly work experience, Pamela has worked in economic development, academia, and business consulting supporting the creation and growth of 100+ life sciences start-ups. Pamela holds a Ph.D. in Molecular Genetics and an MBA from Carnegie Mellon University. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tushar Misra, Chief Manufacturing Officer at Mersana Therapeutics. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tushar covering: How his opportunistic nature led him to several roles, companies and locations across the processing and biopharmaceutical sectorBeing given the task of building a worldwide manufacturing and supply chain infrastructure for the commercial launch of a biologic oncology product globally for TakedaKey components of a strong CDMO partnership ‘beyond checking boxes’ and how the type of product impacts the selection processThe harsh realities of a recent clinical failure for a biopharmaceutical company that impacts employees and patientsHow the explosion of modalities have driven growth across all segments the outsourcing space Tushar Misra is the Chief Manufacturing Officer at Mersana Therapeutics, a biopharmaceutical company specializing in the discovery and development a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need. He has over 30 years of experience in developing drugs that involve small and large molecules and ADCs, as well as the development and management of worldwide commercial supply chains. Prior to Mersana, Tushar was EVP, Head of Technical Development & Manufacturing at Laronde, where he led the process development and manufacturing team for end-to-end manufacturing for RNA products. In addition, Tushar worked at Takeda Pharmaceuticals in several positions of increasing seniority, most recently as VP & Head, Global Oncology and Biologics Operations. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Mike Martin, Chief Executive Officer at CAI. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Mike, covering: How a passion for engineering led to a lifetime in life sciences - including 32 years with Eli LillyWhy working in China, Puerto Rico, and Ireland and the exposure to new cultures changed this ‘mid-west farm boy’s view of the worldA very short attempt at retirement... and what tempted Mike back into the working worldLessons learned from years of being the client, but also knowing when to dial down the client voice as a service provider As the CEO of CAI, Mike Martin guides a team of 800+ across the US, Europe, and APAC for the global professional services firm focused on engineering and quality consulting. With over 30 years in the pharmaceutical industry, including decades at Eli Lilly, Mike has experience in engineering, operational leadership, engineering leadership, and large-scale project management in diverse global settings, specifically major capital projects in the US, Puerto Rico, China, and Ireland. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Kathy Fernando, Senior Vice President and Global Head of Pfizer Ignite and Pfizer CentreOne. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kathy, covering: How the forgotten step-child that is mRNA rose to the top of the technology vaccine treeSome of the key ingredients of the secret sauce that has dramatically improved the success of Pfizer’s R&D engineHow Pfizer Ignite is positioned to assist capital-constrained biotech innovators, side-by-side, in several waysThe intentional, sacrifice and discipline required to have a good balance of career success and healthy home lifeAnd what it’s like working with Albert Bourla, Chief Executive Officer at Pfizer Kathy is a Senior Vice President and Global Head of the Pfizer Ignite Organization, and the Global Head of Pfizer CentreOne, within the Business Innovation Office at Pfizer. Her prior roles at Pfizer include Head of Worldwide Research, Development & Medical Operations and Head of mRNA scientific strategy. She also led efforts to develop an ambitious and holistic scientific strategy for mRNA across therapeutic areas as well as a well-orchestrated plan for execution. Prior to joining Pfizer, she worked at Deloitte, helping address diverse business needs for pharmaceutical and biotech companies in the US and EU. Kathy has a Ph.D. in Immunology from the University of Pennsylvania. Her Ph.D. thesis focused on mRNA vaccine and HIV vaccine development. She has a bachelor’s degree in biotechnology from the Indian Institute of Technology (I.I.T) in Kharagpur, India. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tim Scott, President and CEO, AustinPx. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tim, covering:  The founding story of Pharmatek, and how client centricity and ‘training the hell out of the team’ contributed to the growthHow the niche of being a spray drying expert led to a sale of Pharmatek to Catalent... and why he didn’t last very long post-acquisitionThe disruptive technology and team that got Tim so excited... he came back to the ‘CDMO+’ world in AustinBuilding traction for a game-changing technology for poorly soluble compounds to get it into 100 molecules and commercial products Tim brings more than twenty years of pharmaceutical contract development and manufacturing organization (CDMO) leadership experience. Previously, Mr. Scott was co-founder and president of Pharmatek Laboratories, a CDMO where he led the growth and ultimate sale of the company to Catalent. He currently serves on the boards of multiple organizations, including Avelas Biosciences, DTx Pharma, CONNECT, BIOCOM, and the University of California, San Diego’s Dean’s Advisory Council for the Division of Biological Sciences. He previously served on the board of Zacharon Pharmaceuticals (sold to BioMarin in 2014). At UC San Diego, Tim has founded or supported multiple biotech spinouts including Zacharon, TEGA therapeutics, LipoNexus, Knoubis Bio, Nerio and Augment Biosciences. Mr Scott earned his BA in Biochemistry from UC San Diego and his JD from the University of San Diego. He is a member of the California Bar. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Graham Wylie, Executive Chairman at the Medical Research Network (MRN). Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Graham, covering: Transitioning from Pfizer’s in-house R&D team to a senior commercial BD role at ParexelThe brutal experience of leading an MBO deal and why you should go into any deal with ‘your eyes open'How the fast-paced CRO world has evolved over the last 20 years, and what the future may hold for the clinical trials spaceHow Graham built an entrepreneurial, family business with a view on the long term plan that includes his wife and kidsHow being used to fast growth as a specialist CRO better prepared MRN for the impact of C19 and 90% growth Dr Graham Wylie graduated in pharmacology in 1982 and then in medicine in 1987. He moved into the Pharma industry in 1989, spending 10 years at Pfizer and 5 years at Parexel in many different forms of clinical trial management before joining Healthcare at Home to create a trials division. He led an MBO to make this a separate company in 2006 and was CEO and majority owner for 16 years, until September 2022, when he passed over the CEO role to one of his (younger) co-founders, and became Executive Chairman. Through that period MRN enjoyed an average growth rate of 35% through feast and famine and continues to be one of the fastest-growing founder-led businesses in the UK. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:   James Edgar, Chief People Officer at Sygnature DiscoveryAndrew Mears, CEO and Co-founder at Lead CandidateLaura Child, Head of Research and Strategy at ramarketing   Your host, Raman Sehgal, discusses pharmaceutical and biotechnology talent challenges and solutions with his guests, covering: Where the industry-wide talent challenge originates, and practical solutions of how companies can take steps to overcome itThe role of a talent attraction team, a recruitment expert, and your employer brand in getting ahead of the curve when it comes to building a people pipelineMapping and flawlessly executing your employee experience value proposition when attracting, onboarding and engaging your starsStaff retention challenges across the board and when things go wrong with your people James Edgar has been in post for 12 months and has joined to support the growth of the company into its next phase with the development of Sygnature’s Employee Value Proposition. He has over 20 years in the People and Human Resources field. He comes with multi-sector experience from Financial Services, Manufacturing, Facilities Management and more recently from Advertising and Media sector with WPP. Andrew Mears is CEO and Co-founder of Lead Candidate, a specialist talent acquisition consultancy exclusively supporting the global pharma and bio-outsourcing sector. He has more than two decades of experience working in human resources and talent, developing and delivering talent initiatives to help fast-growing companies achieve ambitious change and growth agendas. Having built an impressive career as Program Director in some of the largest multinational CROs, delivering high-value and high-complexity global trials, from Ph 1 through Ph 3, Laura joined ramarketing as Head of Research and Strategy. In this role, Laura works closely with a team of senior marketers and Sector Specialists to conduct in-depth research projects to deliver data-driven brand and growth strategies for clients. Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Alok Tayi, Founder and CEO at Vibe Bio.   Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Alok, covering:   The personal story that motivated and inspired Alok to create a rare disease platform focused entirely on creating an ecosystem focused on high potential medicines.Lessons from ‘the grind’ of raising over $100m in capital, and why you need a ‘Minimal Viable Investor’ (MVI)The macro impact of Covid-19 in highlighting the importance of medicines - and why this is a time for optimism, innovation and technology in biotech.The catch-22 of inflection points for biotechs and how that impacts access to capital. And whether AI could play a pivotal role.How CDMOs and CROs need to evolve away from just the fee-for-service model to explore longer-term, partnership-led alternatives.   Alok has 15 years of experience as a scientist and 12 as a serial entrepreneur. After completing postdoctoral work at Harvard University with George Whitesides, Alok started two pharma SaaS companies, PreScouter and TetraScience, which employ several hundred people combined and have more than four hundred customers. He also launched and led the life sciences division of Egnyte, a cloud content governance company based in California, and grew the business to a 60-person team and eight-figure run rate.   Alok founded Vibe Bio after his daughter was hospitalized at birth and he learned first-hand that the biggest obstacle to developing treatments isn’t finding potential therapies — it’s funding them. Vibe Bio is helping patients in similar situations overcome that obstacle by scaling the development of treatments for rare disorders sustainably for the first time. He holds a B.S. from Cornell and a Ph.D. from Northwestern, both in Materials Science & Engineering.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!   Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this special episode of Molecule to Market, instead of going inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, you'll hear a special announcement about the show moving to Toronto! The announcement reveals why our show sponsor, ramarketing is opening a new office in Canada and what this means for your favorite podcast and host. Listen to the short episode to hear:   About the drivers behind ramarketing's decision to establish a second office in North AmericaWhy the agency selected Toronto, or T'rono as the locals sayDiscover what the move means for Raman and his family, in addition to the ramarketing team and future talent acquisitionThe benefits of locating to one of the most diverse cities in the worldHow ramarketing and Molecule to Market plan to tap into the thriving life science ecosystem and 'Pill Hill' located in the Greater Toronto Area (GTA)   The announcement is a real milestone for ramarketing as a business and for Molecule to Market.   The show hopes the move will provide access to even more incredible guests! Giving our host access to more people to outreach and hopefully attracting new people - listeners, followers and guests.   So, from late August onwards, you'll be hearing from Molecule to Market in a new location. We'll keep our loyal listeners informed of how the move is going and what life is like for Raman, his family and our team in Toronto. Until then....take care. Thank you for listening!   Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!   Molecule to Market is sponsored and funded by ramarketing, an international mark

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Barbara Morgan, Global Vice-President of Pharma and Biotechnology at Kerry.   Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Barbara, covering: Believing in herself and being brave enough to leave a company that felt like family in a job that she lovedWhy Pharma has proved itself to be indispensable, while the biopharma slowdown is just a blipThe difference between mentors and sponsors, and why you need a blend of bothLessons for mastering M&A assessment and integration for prioritizing impact   Barbara Morgan is Global Vice-President, Pharma, and Biotechnology at Kerry. Prior to that she worked at LLS Health (part of Lubrizol) from 2014 until 2021 and was named General Manager in 2018.   With a Ph.D. in Organic Chemistry from the University of Pennsylvania (US), Dr Morgan has more than 15 years of experience in the Life Science industry, covering pharmaceutical, nutraceutical, and medical devices.  She has published numerous articles in peer-reviewed journals and holds patents, including one on the treatment of cancer stem cells.   Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!   Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Marcel Velterop, CEO and Member of the Board at Primopus. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Marcel, covering: Tips for technical people looking to transition and navigate into a commercial career pathWhy the CDMO business is not for the faint-hearted given the brutal focus on execution and resultsInsights from a lifetime of doing business in India and the key components of a successful tech transfer across multi-national sitesHow oligonucleotides have gone from niche to mainstream, and why an oligos platform presents a major new tool in the healthcare toolbox Marcel holds a masters degree in chemical engineering from Delft University of Technology and started his career at DSM where he spent 14 years in various roles of growing responsibility. He then joined Dr Reddy’s Laboratories CPS, a CDMO, and subsequently worked for large Indian providers like Sai Life Sciences and Jubilant Biosys. He gained extensive international experience during his 4 years in the US and now over 15 years in Switzerland and aims to work with cultural differences globally and build productive collaborations. He found purpose in the pharma industry and helping drive innovation as a service provider in the CDMO and CRO industries. During the Covid times, an opportunity presented itself to work for a large India CDMO, who had acquired a GMP API plant just outside Basel, Switzerland. As CEO of Primopus he is building a hybrid business model with complex RSMs and intermediates supplied out of the Swiss site with full backward integration from the large capacity available in India at its parent company. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jesse McCool, Co-Founder and CEO at Wheeler Bio. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jesse, covering: His journey from the Lonza bench to the boardroom as CEO of Cytovance CEO before becoming a founderBuilding a CDMO from a blank canvas via a pit stop of C19 testingWhat makes Oklahoma City an attractive place to do business with its mixed blend of life science, tech and biomanufacturing expertiseHow Wheeler’s hub and spoke satellite business model and platform is changing the CDMO business model Jesse McCool is the Co-Founder and CEO of Wheeler Bio, an agile, small-batch biologics drug substance manufacturer focused on addressing unmet needs in the translational space. He has over 20 years of biologics development and manufacturing experience in biotech and CDMO environments. He previously held executive and technical positions at Cytovance Biologics, Lonza, Lallemand/Mascoma, Dartmouth, and Clean Harbors. He joined Cytovance Biologics in 2013 to build out and lead the process development organization. The company was acquired by Hepalink in 2015 after which he was named Director, Chief Technical Officer and eventually, Chief Executive Officer. Jesse left Hepalink following the successful HK IPO in 2020 ($500MM USD) to join OKC-based venture studio, Echo Investment Capital, as Entrepreneur-In-Residence. He co-founded and launched Wheeler Bio in 2021. He also serves on the Governor’s Council for Workforce and Economic Development (State Commerce) and works on numerous workforce development initiatives in the biomanufacturing sector. Jesse earned a Ph.D. from the University of Massachusetts at Amherst and completed his postdoctoral work at Dartmouth (Hanover, NH) and Delft University of Technology (The Netherlands). In addition to his industry experience, Jesse is an established public speaker, researcher, and peer-reviewed journal author and contributor. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Lung-I Cheng, Vice President of Cell & Gene Therapy at AmerisourceBergen. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Lung-I, covering: His take on the different models of healthcare he has seen globally, and the value they do and don’t deliver to patientsThe access, and infrastructural challenges of CGT products and ways to bring the cost of goods downWhy CGT is the therapy of the future... but why we must remember it’s not the only modality out thereWhat the future looks like for CGT and exploring what happens when we have a treatment that can treat a lot more patients Lung-I Cheng, Ph.D., is Vice President, Cell and Gene Therapy, leading AmerisourceBergen’s Cell and Gene Therapy (CGT) service line. In his role, he advances AmerisourceBergen’s CGT strategy with a focus on expanding the company’s portfolio of services to better support CGT innovators throughout the commercialization journey. Before joining AmerisourceBergen, he spent a decade in biopharma, most recently serving as the head of Global Value & Access for Cell Therapies, Pipeline, and Business Development at Takeda. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Shawn Singh, Chief Executive Officer and Director at Vistagen Therapeutics. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Shawn, covering: What life is like running a public company and how that is impacted depending upon the season of the capital marketsThe ups, downs and pivots of a biopharmaceutical company that’s led it down a mission of transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disordersHow the pandemic has magnified mental health issues and their prevalence among young people, and why finding a radically social transformative treatment is neededWhy collaboration is key when developing several drug candidates and how partnerships can happen at any stage of the lifecycleHis views on CROs, CDMOs, what is essential to outsource in the vendor universe... and the most critical asset to a biotech boss Shawn is an experienced public company Chief Executive Officer and Director. He has over 30 years of experience working with private and public biotechnology, medical device, and pharmaceutical companies, a venture capital firm, and a profitable contract research and development organization (CRO), serving in numerous senior management roles. He’s an attorney and a member of the California State Bar with a Juris Doctor from the University of Maryland Francis King Carey School of Law. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Wayne Woodard, CEO at Argonaut Manufacturing Services. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Wayne, covering: How a career in the famously outsourced semiconductor industry benefited his route into the outsourced life science spaceThe basic thesis that led to the start-up of Argonaut and the deliberate intention to ‘skate to where the puck will be’Wayne’s aim (and achievement) of creating something special that would also help people and pay forwardKey considerations and benefits of being located on the West Coast of the USA... including wine With 35 years of management experience in operations, supply chain and general management, Wayne Woodard’s primary focus (in three different industries) has been on building global operations capabilities with particular emphasis on working with external manufacturing services companies. Before founding Argonaut, Wayne most recently worked at Thermo Fisher/Life Technologies through its Ion Torrent acquisition. He previously worked at Affymetrix, Electroglas and Ridge Technologies. Wayne began his career in manufacturing at Sun Microsystems. Wayne focuses intensely on execution and detail, which is why he also bottles his own wine. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Richard Weaver, Founder and Managing Director at Drug Discovery Solutions. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Richard, covering: How his curiosity to learn at AZ led him to realizing he was an entrepreneurThe opportunistic start-up story and impressive growth journey of XenoGesis up to the eventual, successful sale to Sygnature Discovery in 2020Lessons learned and milestone moments of a scientific entrepreneurWhy biotechs are here to stay... outsourcing is here to stay... but why offshoring is not Richard is Founder and Managing Director of Drug Discovery Solutions Limited. Previously CEO and founder of XenoGesis, he grew and led the successful sale of the business to Sygnature Discovery in 2020. Prior to that, he spent 14 years at AstraZeneca. He is an expert of all aspects of R&D including Due Diligence of companies/assets. Specialist in Drug Metabolism & Pharmacokinetics (DMPK) from Hit Identification (HI) to Candidate Drug (CD) nomination and pre-clinical development. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Vishnu Dwadasi, Director of Manufacturing at Ashvattha Therapeutics Inc.   Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Vishnu, covering: Lessons learned from 15 years in CDMOs and consulting, before joining a start-up drug development companyWhat he’s learned from working with and managing CDMOs all over the worldWhy many CDMOs are behind the eight-ball... fancy marketing meets chaotic operationsThe challenge of scaling up through phases as a drug sponsor, and the evolving needs when it comes to outsourcingMajor frustrations as a client in a post-covid world and the one area every CDMO needs to invest in moving forward   Vishnu Dwadasi is currently a Director of Manufacturing at a biopharmaceutical start-up company, Ashvattha Therapeutics, leading drug programs from pre-clinical to commercialization. Vishnu brings over a decade of experience in life sciences with a unique background in pharmaceutical operations, consulting, and business development. He has developed extensive experience shepherding complex drug development programs from early clinical development to full-scale commercial manufacturing and distribution. Along with his drug development experience, Vishnu has gained expertise in operations and implementing technology solutions for life sciences companies. Vishnu earned an MBA from Duke University and a B.S. in Health Sciences from Purdue University. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.